PRDM9 and leukemia: As a survival mechanism to resist cytotoxic stress, leukemia cells are found to increase autophagy during the treatment of chemotherapy including cytarabine and daunorubicin [12, 19, 29], or targeted therapy such as BET inhibitors [20], histone methyltransferase inhibitors [30], BCL2 inhibitors [31], to counteract therapeutic effect.